CONTRIBUTION AGREEMENT (351)Contribution Agreement • September 10th, 2019 • Monopar Therapeutics • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 10th, 2019 Company Industry JurisdictionThis Contribution Agreement (this “Agreement”) is entered into as of August 25, 2017 (the “Effective Date”), among TacticGem LLC, a Delaware limited liability company (the “Company”), Monopar Therapeutics Inc., a Delaware corporation (“Monopar”), Gem Pharmaceuticals, LLC, an Alabama limited liability company (“Gem”) and Tactic Pharma, LLC, an Illinois limited liability company (“Tactic”, and collectively with Gem, the owners of 100% of the issued and outstanding limited liability company interests of the Company). The Company, Monopar, Tactic, and Gem are sometimes hereinafter referred to collectively as the “Parties”, and each individually as a “Party”.
CONTRIBUTION AGREEMENT (351)Contribution Agreement • March 26th, 2018 • Monopar Therapeutics • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 26th, 2018 Company Industry JurisdictionThis Contribution Agreement (this “Agreement”) is entered into as of August 25, 2017 (the “Effective Date”), among TacticGem LLC, a Delaware limited liability company (the “Company”), Monopar Therapeutics Inc., a Delaware corporation (“Monopar”), Gem Pharmaceuticals, LLC, an Alabama limited liability company (“Gem”) and Tactic Pharma, LLC, an Illinois limited liability company (“Tactic”, and collectively with Gem, the owners of 100% of the issued and outstanding limited liability company interests of the Company). The Company, Monopar, Tactic, and Gem are sometimes hereinafter referred to collectively as the “Parties”, and each individually as a “Party”.
CONTRIBUTION AGREEMENT (351)Contribution Agreement • December 20th, 2017 • Monopar Therapeutics • Pharmaceutical preparations • Delaware
Contract Type FiledDecember 20th, 2017 Company Industry JurisdictionThis Contribution Agreement (this “Agreement”) is entered into as of August 25, 2017 (the “Effective Date”), among TacticGem LLC, a Delaware limited liability company (the “Company”), Monopar Therapeutics Inc., a Delaware corporation (“Monopar”), Gem Pharmaceuticals, LLC, an Alabama limited liability company (“Gem”) and Tactic Pharma, LLC, an Illinois limited liability company (“Tactic”, and collectively with Gem, the owners of 100% of the issued and outstanding limited liability company interests of the Company). The Company, Monopar, Tactic, and Gem are sometimes hereinafter referred to collectively as the “Parties”, and each individually as a “Party”.
CONTRIBUTION AGREEMENT (351)Contribution Agreement • November 9th, 2017 • Monopar Therapeutics • Delaware
Contract Type FiledNovember 9th, 2017 Company JurisdictionThis Contribution Agreement (this “Agreement”) is entered into as of August 25, 2017 (the “Effective Date”), among TacticGem LLC, a Delaware limited liability company (the “Company”), Monopar Therapeutics Inc., a Delaware corporation (“Monopar”), Gem Pharmaceuticals, LLC, an Alabama limited liability company (“Gem”) and Tactic Pharma, LLC, an Illinois limited liability company (“Tactic”, and collectively with Gem, the owners of 100% of the issued and outstanding limited liability company interests of the Company). The Company, Monopar, Tactic, and Gem are sometimes hereinafter referred to collectively as the “Parties”, and each individually as a “Party”.